Your browser doesn't support javascript.
loading
HDL mimetic CER-001 targets atherosclerotic plaques in patients.
Zheng, Kang He; van der Valk, Fleur M; Smits, Loek P; Sandberg, Mara; Dasseux, Jean-Louis; Baron, Rudi; Barbaras, Ronald; Keyserling, Constance; Coolen, Bram F; Nederveen, Aart J; Verberne, Hein J; Nell, Thijs E; Vugts, Danielle J; Duivenvoorden, Raphaël; Fayad, Zahi A; Mulder, Willem J M; van Dongen, Guus A M S; Stroes, Erik S G.
Afiliação
  • Zheng KH; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: k.h.zheng@amc.nl.
  • van der Valk FM; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: f.m.valkvander@amc.nl.
  • Smits LP; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: l.p.smits@amc.nl.
  • Sandberg M; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: marasandberg@hotmail.com.
  • Dasseux JL; Cerenis Therapeutics Holding, Toulouse, France. Electronic address: dasseux@cerenis.com.
  • Baron R; Cerenis Therapeutics Holding, Toulouse, France. Electronic address: baron_rudi@yahoo.fr.
  • Barbaras R; Cerenis Therapeutics Holding, Toulouse, France. Electronic address: barbaras@cerenis.com.
  • Keyserling C; Cerenis Therapeutics Holding, Toulouse, France. Electronic address: keyserling@cerenis.com.
  • Coolen BF; Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: b.f.coolen@amc.nl.
  • Nederveen AJ; Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: a.j.nederveen@amc.nl.
  • Verberne HJ; Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: h.j.verberne@amc.nl.
  • Nell TE; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: t.nell@vumc.nl.
  • Vugts DJ; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: d.vugts@vumc.nl.
  • Duivenvoorden R; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: raphael.duivenvoorden@gmail.com.
  • Fayad ZA; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: zahi.fayad@mssm.edu.
  • Mulder WJM; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: wjmmulder@gmail.com.
  • van Dongen GAMS; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: GAMS.vanDongen@vumc.nl.
  • Stroes ESG; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: e.s.stroes@amc.nl.
Atherosclerosis ; 251: 381-388, 2016 08.
Article em En | MEDLINE | ID: mdl-27263077
ABSTRACT
BACKGROUND AND

AIMS:

Infusion of high-density lipoprotein (HDL) mimetics aimed at reducing atherosclerotic burden has led to equivocal results, which may relate in part to the inability of HDL mimetics to adequately reach atherosclerotic lesions in humans. This study evaluated delivery of recombinant human apolipoprotein A-I (apoA-I) containing HDL mimetic CER-001 in carotid plaques in patients.

METHODS:

CER-001 was radiolabeled with the long-lived positron emitter zirconium-89 ((89)Zr) to enable positron emission tomography with computed tomography (PET/CT) imaging. Eight patients with atherosclerotic carotid artery disease (>50% stenosis) received a single infusion of unlabeled CER-001 (3 mg/kg), co-administered with 10 mg of (89)Zr-labeled CER-001 (18 MBq). Serial PET/CT imaging and contrast enhanced-magnetic resonance imaging (CE-MRI) were performed to evaluate targeted delivery of CER-001.

RESULTS:

One hour after infusion, mean plasma apoA-I levels increased by 9.9 mg/dL (p = 0.026), with a concomitant relative increase in the plasma cholesterol efflux capacity of 13.8% (p < 0.001). Using serial PET/CT imaging, we showed that arterial uptake of CER-001 expressed as target-to-background ratio (TBRmax) increased significantly 24 h after infusion, and remained increased up to 48 h (TBRmax t = 10 min 0.98; t = 24 h 1.14 (p = 0.001); t = 48 h 1.12 (p = 0.007)). TBRmax was higher in plaque compared with non-plaque segments (1.18 vs. 1.05; p < 0.001). Plaque TBRmax correlated with local plaque contrast enhancement (r = 0.56; p = 0.019) as assessed by CE-MRI.

CONCLUSIONS:

Infusion of HDL mimetic CER-001 increases plasma apoA-I concentration and plasma cholesterol efflux capacity. Our data support the concept that CER-001 targets plaque regions in patients, which correlates with plaque contrast enhancement. These clinical findings may also guide future nanomedicine development using HDL particles for drug delivery in atherosclerosis. CLINICAL TRIAL REGISTRATION Netherlands Trial Registry - NTR5178. http//www.trialregister.nl/trialreg/admin/rctview.asp?TC=5178.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfolipídeos / Proteínas Recombinantes / Apolipoproteína A-I / Placa Aterosclerótica Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfolipídeos / Proteínas Recombinantes / Apolipoproteína A-I / Placa Aterosclerótica Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article